, there is considerable drug-resistant HIV in both untreated 4 and treated 5, 6 individuals in low-and middle-income countries and sustainability of ART programmes is uncertain 7 . Drug-free durable HIV-1 suppression is therefore an urgent global priority.
Thus far, the only documented case of sustained HIV remission is the Berlin patient, who received two allogeneic HSCTs using cells from a homozygous CCR5Δ32 (CCR5Δ32/Δ32) donor 1 . This 32-base-pair deletion prevents CCR5 expression, rendering these cells resistant to infection with HIV variants that interact with the CCR5 coreceptor 8 .
The only other case of a patient with HIV-1 who was transplanted with CCR5Δ32/Δ32 cells and interrupted ART was the 'Essen patient '9 . In this case, ART was interrupted one week before allogeneic HSCT and rapid viral rebound of a pre-existing minority HIV-1 variant, which was able to infect cells through the alternative CXCR4 coreceptor, was observed three weeks later 9, 10 . Such pre-existing CXCR4 variants were not observed in the Berlin patient 11 . Three other cases transplanted with wild-type CCR5 cells experienced viral rebound 12, 32 or 41 weeks after ART interruption despite a considerable reduction of the HIV reservoir 12, 13 . We report an individual diagnosed with HIV-1 infection in 2003, with a CD4 nadir of 290 cells mm −3 and a baseline HIV-1 plasma viral load of 180,000 copies per ml. ART was initiated with tenofovir disoproxil fumarate, emtricitabine and efavirenz in 2012.
In December 2012, the individual was diagnosed with stage IVb (nodular sclerosing) Hodgkin's lymphoma. Hodgkin's lymphoma was refractory to first-line chemotherapy (doxorubicin, bleomycin, vincristine and dacarbazine) and a number of salvage regimens, including etoposide, methylprednisolone, cytarabine and cisplatin; anti-CD30 monoclonal antibody (Brentuximab) and mini-LEAM (lomustine, etoposide, cytarabine and melphalan) were used. ART was switched to tenofovir disoproxil fumarate, emtricitabine and raltegravir during periods of chemotherapy for Hodgkin's lymphoma; there was a 5-day episode of ART interruption in late 2015 with an HIV-1 plasma viral load of 1,500 copies per ml that did not reach the viral set point. On the basis of resistance mutations K65R and M184V in reverse transcriptase as well as E157Q in integrase, the regimen was switched to rilpivirine, lamivudine and dolutegravir; viral suppression was subsequently achieved.
Mobilization of autologous peripheral blood stem cells failed despite the use of CXCR4 antagonists, thus precluding standard autologous HSCT. Complete metabolic remission as confirmed by computed tomography and positron-emission tomography criteria was achieved with ifosfamide, gemcitabine and vinorelbine (IGEV) chemotherapy in March 2016.
An unrelated (nine out of ten) donor was identified from an international registry with one allelic mismatch at HLA-B by high-resolution HLA typing, who was CCR5Δ32/Δ32 (Extended Data Table 1 and Methods). No fully matched donors were identified in the registry. The patient underwent conditioning with lomustine, cyclophosphamide, Letter reSeArCH ara-C and etoposide followed by infusion of 3.6 × 10 6 CD34 + cells per kg. In vivo T cell depletion was achieved by anti-CD52 antibody (alemtuzumab), 10 mg daily for 5 days (days −7 to −3) before transplantation and graft-versus-host disease prophylaxis used cyclosporine-A with a short course of methotrexate. ART was continued throughout with rilpivirine, lamivudine and dolutegravir (Fig. 1a) . Allogeneic HSCT was relatively uncomplicated and the patient was discharged on day 31 after transplantation. Reactivation of both Epstein-Barr virus and cytomegalovirus (CMV) occurred at day 85 after transplantation, requiring treatment with anti-CD20 monoclonal antibody (rituximab) and ganciclovir, respectively. At day 77 after transplantation, the patient presented with fever and gastrointestinal symptoms. Gastric, duodenal and colonic biopsies were consistent with grade 1 graft-versus-host disease, which resolved without intervention.
Full-donor chimerism was achieved in the whole-leukocyte and CD3 + T cell fractions from day 30 after transplantation and maintained in both cell fractions throughout (Fig. 1b) . Host genotype was homozygous wild-type CCR5 before allogeneic HSCT, and became CCR5Δ32/ Δ32 after transplantation (Fig. 1c) , with loss of CCR5 surface expression from circulating CD4 and CD8 T cells (Fig. 1d) . At 180 days after transplantation, cyclosporine-A was discontinued. Computed tomography and positron-emission tomography scans at 120 days and 365 days after transplantation confirmed complete metabolic remission with no subsequent relapse. Post-transplant white blood cell counts and lymphocyte subsets returned to pre-transplant levels (Extended Data Fig. 1 ), except for CD4 counts, which have been slower to recover (Fig. 1a) .
ART was maintained after HSCT and analytical treatment interruption was initiated at day 510 (September 2017). Weekly analyses of plasma viral load were performed for the first three months and monthly thereafter. HIV-1 plasma viral load remained undetectable thereafter with a limit of detection of less than one copy of RNA per ml (Fig. 1a) . Plasma concentrations of tenofovir disoproxil fumarate, lamivudine and dolutegravir were negative by high-performance liquid chromatography at day 648 after transplantation, and a panel of all currently available antiretroviral drugs tested negative by liquid chromatography mass spectrometry at 973 days after transplantation. HIV-1 DNA associated with total peripheral blood mononuclear cells (PBMCs) fell below the limit of detection after transplantation (Fig. 1b) . Total DNA in CD4 T cells at day 876 after transplantation was undetectable in all replicates by ultra-sensitive qPCR (<0.65 HIV LTR copies per million cells and <0.69 HIV-1 Gag copies per million cells) and in 7 out of 8 replicates of the ultra-sensitive HIV-1 LTR ddPCR 14 ; in one replicate, a low-level signal was observed. Such occasional positive signals were also observed in the Berlin patient 15 and may reflect a false ddPCR signal, potential contamination or evidence of very low levels of persistence of HIV-infected cells that either did not contain a fully replication-competent virus or were unable to lead to recrudescence given that the vast majority of target cells are incapable of being infected with the HIV CCR5-tropic variants of this patient (Fig. 2) . HIV-1 DNA and RNA were also repeatedly undetectable in whole blood when tested with SAMBA II, a point-of-care isothermal amplification method (limit of detection, 284 copies per ml; 95% confidence interval, 214-378 copies per ml) 16 . Blood was obtained for a modified quantitative viral outgrowth assay 17, 18 at 3 time points after HSCT on day 217 (on ART), days 678 and 876 (off ART) after transplantation. Analysis of the quantitative viral outgrowth assays indicated that HIV-1 virus was undetectable on all occasions, giving an estimation of the reservoir in infectious units per million resting CD4 T cells of less than 0.286, less than 0.309 and less than 0.063, respectively. Pooling the results from the 3 quantitative viral outgrowth assays on a total of 24 million resting CD4 T cells gives an estimate of less than 0.029 infectious units per million cells.
We next sought to confirm that the post-transplant CD4 cells lacked expression of CCR5 and were resistant to HIV-1 infection ( Fig. 2 and Extended Data Fig. 2 ). CD4 T cells from the study patient were challenged in vitro with the CCR5-tropic viruses Ba-L and ZM247, and productive HIV-1 infection over seven days was measured by (i) intracellular staining for HIV-1 p24 protein (Fig. 2a, b) and (ii) infectivity of culture supernatants on indicator cell lines that respond to expression of the HIV Tat protein (Extended Data Fig. 2) . In contrast to an HIVnegative donor, post-transplant cells from the study patient could not be infected with the CCR5-tropic viruses Ba-L and ZM247 (Fig. 2a, b) . The cells of the study patient were then challenged with the canonical CXCR4-tropic HIV-1 virus NL4-3. As expected, infection was observed in cells and supernatants from both the patient and an HIV-negative donor (control) (Fig. 2a, b and Extended Data Fig. 2) .
To determine whether the study patient was infected with CCR5-or CXCR4-using virus (or both), we deep-sequenced the V3 loop in HIV-1 envelope (the key determinant of coreceptor usage) and computational Letter reSeArCH algorithms predicted CCR5 tropism 19, 20 . For phenotypic verification, we first performed single-genome sequencing of gp120 from pre-transplant PBMCs by limiting-dilution PCR 21, 22 (Fig. 2c) . These single genome gp120 amplicons were cloned into gp160 expression vectors and used to generate virions that were pseudotyped with patientderived envelope protein 21 ( Fig. 2d) , before infection of indicator cells that expressed either CCR5 or CXCR4. As predicted from the genotype, robust infection was observed in CCR5-but not CXCR4-expressing cells (Fig. 2d ).
Analyses of both antibody and T cell responses were carried out to further investigate the absence of persistent HIV-1 infection and antigenic stimulation. Western blot analysis of antibodies demonstrated loss of p24, p31 and multiple other bands between pre-and post-transplant time points in pattern that is similar to patterns previously found in other transplanted patients who have remained on ART 23 (Fig. 3a  and Extended Data Table 2 ), while antibodies against envelope protein gp160 persisted and standard enzyme-linked immunosorbent assay (ELISA) for Env antibodies shows Env expression persisted (Fig. 3a, b) . Low-sensitivity VITROS analysis and antibody avidity assays were also consistent with loss of HIV antigens following allogeneic HSCT 15 ( Fig. 3c, d ). CD8 and CD4 T cell virus-specific responses were determined following stimulation with HIV-1 Gag-and CMV pp65-overlapping peptide pools (Fig. 4a) . Small Gag-specific IFNγ + T cell responses were identified by intracellular staining and CD4 multifunctional responses (IFNγ, CD107a, TNF and IL-2) were detected before HSCT (day −35) but not at days 72, 96, 510 and 819 after the procedure (Fig. 4a-c) . No HIV-1-specific T cell responses were detected to Nef, Pol and Env peptide pools at days 96 and 819 after transplantation (Extended Data Fig. 3 ). By contrast, CMV-specific T cell responses were detected both before and after HSCT, albeit at reduced frequencies after HSCT compared to before HSCT ( Fig. 4a-c) .
Both antibody and T cell responses observed here are highly similar to observations in the Berlin patient 1, 15 . Important similarities between the two cases were CCR5-tropic HIV-1 infection and receipt of a CCR5Δ32/Δ32 transplant. Graft-versus-host disease prophylaxis was very similar and used standard regimens (cyclosporine-A and mycophenolate mofetil compared to cyclosporine-A and methotrexate) that in randomized studies have shown similar outcomes 24 . In both staining at day three and day seven after infection using CCR5-and CXCR4-tropic viruses. Data are mean ± s.e.m. and are representative of three independent experiments each conducted in duplicate. Note, data from the index patient are zero. c, Maximum likelihood phylogenetic tree showing single genome env C2-V5 sequences (HXB2 env nucleotides 367-1,533) from PBMCs before HSCT. NL4.3, Ba-L and two subtype D sequences from GenBank were also used. Red nodes indicate >70% bootstrap support. gp120 amplicons from sequences marked with an asterisk were cloned into a clade B gp160 Env plasmid. Virus env sequences marked by red asterisks generated infectious virus particles when co-transfected into HEK293T cells with the envelope-deficient full-length HIV plasmid encoding luciferase (NL4-3ΔEnv Luc). Black asterisks indicate sequences that did not generate infectious viruses. Scale bar, nucleotide substitutions per site. d, Pseudoviruses from c were used to infect U87 cells that express either CXCR4 or CCR5. RLU, relative luminescence units. A dual tropic pseudovirus (WEAU-d15.410.787) was produced in parallel as a positive control for infection (red line). a-d, Experiments were performed independently three times with similar results (sample size n = 1 healthy control donor and n = 1 index patient for a and b; sample size n = 9 clones tested in d). Letter reSeArCH cases, there was probable mild graft-versus-host disease, which may have contributed to the loss of HIV-1 infected cells. Finally, both achieved and maintained full-donor chimerism in peripheral blood that might have contributed to reduced reservoir size 23, 25 . Notable differences were that before allogeneic HSCT, our patient was homozygous CCR5 wild-type compared to the heterozygous CCR5Δ32/WT genotype observed in the Berlin patient. Our patient received a reduced intensity conditioning regimen, which consisted exclusively of chemotherapy agents with known activity against lymphoma 26 , whereas the Berlin patient received total body irradiation in conjunction with cyclophosphamide as the conditioning regimen. For lymphodepletion, our patient received the anti-CD52 antibody campath whereas the Berlin patient was treated with anti-thymocyte globulin. Our patient was treated with a short course of anti-CD20 antibody for reactivation of Epstein-Barr virus. There has been recent interest in the potential for anti-B cell therapy to disrupt B cell follicles that are known to contain persistent HIV in lymphoid tissues 27 , although we think this mechanism is unlikely to be related to the remission observed here. Finally, this patient achieved full remission after a single allogeneic HSCT whereas the Berlin patient experienced a relapse of acute myeloid leukaemia and received further chemotherapy with an anti-CD33 monoclonal antibody conjugate before a second allogeneic HSCT.
In terms of a way forward, we suggest that CCR5 gene-therapy strategies using stem cells could conceivably be a scalable approach to remission. As considerable graft-versus-host effects are probably important, manifesting as early and sustained full donor chimerism in T cells, an autologous approach needs to achieve high levels of replacement by CCR5-depleted cells. Depletion of the CD4 CCR5 T cells and other potential HIV reservoirs is a major challenge given the toxicities associated with anti-thymocyte globulin and anti-CD52 antibody treatments and the unknown role of anti-proliferative agents such as cyclosporin or methotrexate in clearing infected cells.
This report demonstrates that the Berlin patient was not an anomaly, that remission of HIV infection can be achieved with reduced intensity drug regimens, that a single CCR5Δ32/Δ32 allogeneic HSCT is sufficient and that total body irradiation is not required. Our observation supports the development of HIV cure strategies based on preventing the expression of the CCR5 coreceptor.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-019-1027-4. 
Letter reSeArCH

MEthodS
Data reporting.
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Patient consent pathway. Following the clinical decision in 2015 to undertake allogeneic HSCT for treatment of aggressive lymphoma, the possibility of a CCR5Δ32/Δ32 match was discussed with the patient. International registry searches identified no fully matched (ten out of ten) donors. The only available donors on the international registries were the selected nine out of ten match and two eight out of tenmatches. The nine out of ten donor selected was therefore the best available match, and subsequent testing confirmed that the potential donor was also homozygous for CCR5Δ32. Ultimately, because the best available donor happened to be CCR5 negative, there were no deviations from the standard hospital consent protocol for HSCT, and therefore standard written informed consent for 'LACE conditioned allogenic stem cell transplant' was obtained from the patient.
In December 2015, six months before HSCT, coreceptor usage was inferred from sequencing of plasma RNA that reported CCR5-tropic virus. The potential for remission was then discussed with the patient and that a supervised treatment interruption would be needed to demonstrate successful remission. Ethical approval for treatment interruption, frequent HIV viral load monitoring and tissue sampling was sought using the standard NHS framework in mid to late 2016. The protocol specified that at 12 months after the transplant, if the viral load was consistently <50 copies per ml on treatment with 'target not detected' for at least 6 months on the 2 most recent consecutive visits, ART would be withdrawn and thereafter viral load would be monitored weekly for the first 3 months, monthly for a further 9 months if undetectable at all time points and every 3 months between years 1 and 4. The protocol specified that if assays for the HIV reservoir were deemed negative by a group of UK experts from CHERUB, we would thereafter monitor viral load every six months. The protocol stated that if viral rebound occurred, moderate or severe symptoms would not be expected owing to the likely low viral load in cases in which the donor chimerism is close to 100%. For the assessment and management of risk, the protocol stated that there was a risk of rebound viraemia, symptoms such as fever and other flu-like symptoms and that this would be mitigated by performing regular viral-load testing to detect viral rebound early, restarting ART when we observe at least 2 viral loads above 200 copies per ml one week apart in the absence of any other cause of viral blips, and monitoring the percentage of CD4 cells at least monthly for the first year. UK NHS Health Research Authority Research Ethics Committee approval was obtained in April 2017 with reference number 17/SW/0021, protocol number 16/0594. The patient provided full written, informed consent in July 2017. The interruption did not occur until September 2017, 16 months after transplantation. The patient was registered to the IciStem consortium as IciStem#36. Testing of chimerism. We measured whole leukocyte and T-cell-specific (CD3 selected) chimerism by short tandem repeats analysis with the PowerPlex16 system. Primary cell culture and CD4 isolation. PBMCs were isolated from whole blood by centrifugation on a Lymphoprep (Axis-Shield) gradient. The cells collected at the interface were washed with PBS and stimulated for 3 days in the presence of PHA and IL-2 (10 pg ml ) for a period of 7 days. Culture medium was changed on day 3 and the collected supernatants were stored for analysis. Cells were stained with viability dye (Ghost Dye Violet 450, Tonbo Bioscience) then fixed in 4% paraformaldehyde, permeabilized (BD Perm/ Wash, BD Biosciences) and stained for intracellular p24 using anti-p24 KC57-RD1 conjugated antibody (Beckman Coulter). The percentage of infected cells was monitored by flow cytometry using BD LSRFortessa flow cytometer (BD Biosciences) and analysed by FlowJo software (Tree Star). ZM247
1 was a gift from B. Hahn. Supernatant infectivity assay on HeLa TZM-bl reporter cells. In this assay, infectivity was measured as Tat-induced gene expression of the firefly luciferase reporter after a single round of virus infection. In brief, 10 4 TZM-bl cells per well were seeded in a 96-well white plate in DMEM culture medium supplemented with 10% FCS for 24 h. After this, medium was replaced with supernatant collected from the infection assay at a final dilution of 1/3 and 1/6. After a 48-h incubation, cells were lysed by addition of Steady-Glo luciferase reagent (Promega) and luminescence was read using a GloMax 96 Luminometer (Promega). For analysis, the relative luminescence units were determined after the subtraction of background luciferase activity from control wells containing cells (average of eight replicates) and subtraction of relative luminescence units from wells containing uninfected supernatant (average of six replicates). Next-generation sequencing of HIV-1 Env V3 from genomic DNA. Nested PCR was performed on isolated DNA to amplify the HIV-1 env region 28 . Subsequently, PCR products were cleaned using the QiaQuick PCR purification kit (Qiagen) and amplicons were sequenced using the MiSeq v.2 reagent kit (500 cycles) to yield paired-end reads of 250 bases each. Coreceptor tropism could be predicted by aligning reads to the consensus B sequence and isolating and trimming reads that overlap the entire V3 region. Unique V3 sequences that are supported by 1.75% were used for HIV-1 coreceptor tropism predicted using geno2pheno and PSSM algorithms. Single-genome sequencing from PBMCs before HSCT. Single genomes were generated as follows. Genomic DNA was extracted from total peripheral PBMCs using the Qiagen DNeasy kit. Two rounds of nested PCR were then performed using previously validated primers and Invitrogen High Fidelity platinum Taq polymerase. The 2-kb env amplicons were visualized by agarose gel electrophoresis and Sanger-sequenced using a primer set internal to env. Sequence alignment and phylogenetic tree construction. env amplicons generated by single-genome sequencing were Sanger-sequenced. Before alignment, sequences were trimmed at the 5′ and 3′ ends until base calls consistently reached a quality score ≥30, resulting in 99.9% accuracy of base calls. Patient env nucleotide sequences were aligned at the protein sequence level using MUSCLE v.3.8.31 29 and mapped back to nucleotide, with minor manual adjustments. Sequences from laboratory isolates NL4.3 and Ba-L were included for reference, together with two HIV-1 subtype D reference isolates from the Los Alamos HIV Sequence Database (http://www.hiv.lanl.gov/) to serve as an outgroup. A maximum likelihood phylogeny was estimated using RAxML v.8 30 , with the general time-reversible nucleotide substitution model and gamma-distributed rate heterogeneity. Stationary frequencies of nucleotides were estimated from their counts in the sequences. Clade support was estimated from 1,000 nonparametric bootstrap replicate datasets. The maximum likelihood phylogeny was rooted on the outgroup branch and visualized using FigTree v.1.4.4 (http://tree.bio.ed.ac.uk/software/figtree/). Phenotypic determination of CCR5 or CXCR4 usage by patient-derived Env clones. Selected gp120 amplicons were cloned into a gp160 expression vector and transfected into HEK293T cells with the envelope-deficient full-length HIV plasmid encoding luciferase (NL4-3 ΔEnv Luc). Pseudoviruses were collected, filtered and titrated threefold in U87 cells expressing either CXCR4 or CCR5. A dual tropic pseudovirus (WEAU-d15.410.787) was produced in parallel as a positive control for infection. After a 48-h incubation, cells were lysed by addition of Steady-Glo luciferase reagent (Promega) and luminescence was read using a GloMax 96 Luminometer (Promega). Modified quantitative viral outgrowth assay. The quantitative virus outgrowth assay was performed as previously described 18 with modifications. In brief, total CD4 T cells were isolated from PBMCs by immune-magnetic negative selection (StemCell Technologies). Cells displaying activation markers (CD25, CD69 and/or HLA-DR) were labelled with FITC-conjugated antibodies (Biolegend) and depleted by FITC selection kit (StemCell Technologies). T cells with activation markers adhering to the beads were recovered, additionally activated with phytohaemagglutinin-L (PHA-L, Sigma-Aldrich), seeded in a limiting dilution and co-cultured with SupT1-CCR5 for at least 21 days.
Resting CD4 T cells were recovered from the eluent and cultured in the presence of 100 nM raltegravir and 20 nM efavirenz for 1-3 days to allow unintegrated viral DNA to degrade. Afterwards, resting CD4 T cells were counted, activated with PHA-L, tenfold excess of irradiated allogeneic PBMCs and 10 units per ml IL-2, and seeded in a limiting dilution. The activation mix was washed away 24 h later and SupT1-CCR5 cells were added to each culture well.
The dilution series include replicates at 2.5 million, 0.5 million and 0.1 million CD4 T cells per well as appropriate. Cultures were maintained for at least 21 days. Cells were monitored for syncytia formation, and the supernatant was sampled regularly for p24. The infectious units per million cells were calculated by limiting dilution statistics. Letter reSeArCH (4-6.5 ml) at 170,000g at 4 °C for 30 min, followed by viral RNA extraction using the m2000sp Abbot RealTime HIV-1 Assay device and laboratory-defined applications software from the instrument. HIV-1 RNA copies in the low range were determined by an in-house calibration curve set (range, 10-10 3 absolute copies), which had previously been validated 31 using a standard HIV-1 DNA control from the WHO in the range of 128-0.5 copies per ml. Limit of detection was calculated relative to the plasma volume used in each sample. Quantification of HIV antibodies. Specific HIV-1 antibodies in longitudinal serum samples were tested in a qualitative western blot assay (New Lav Blot I, Bio-Rad). Standard and low-sensitive versions of the VITROS anti-HIV-1 assay (Ortho-Clinical Diagnostics) as well as the limiting avidity antigen assay were measured in same samples as previously described 2 . In brief, four recombinant antigens (HIV-1 Env 13, HIV-1 Env 10, HIV-1 p24 and HIV-2 Env AL) derived from HIV-1 core, HIV-1 envelope and HIV-2 envelope proteins were quantified. The optimized version of the LS-VITROS assay (detuned or low-sensitive version) uses a 1:400 dilution of an HIV-positive sample. The cut-off was set to a ratio of signal:cut-off of 20. The avidity assay measures the capacity of the guanidine to elute low-avidity and low-affinity antibodies after antigen-antibody bonds have formed. The results are reported as an avidity index, which was calculated as a ratio of the ratio of signal:cut-off of the sample incubated in guanidine to the ratio of signal:cut-off of the sample incubated in PBS. Cut-off was established at 0.51. Flow cytometry. The following fluorochrome-conjugated antibodies were used in this study: CD14-BV510, CD19-BV510, CD3-APC Fire 750 or CD3-BV605, CD4-PE/Dazzle 594, or CD4-APC Fire 750, CD8-BV421, CCR5-PE/Dazzle 594, CD56-PE-Cy7 (Biolegend) for surface antigens; and IFNγ-PE-Cy7 (BD Biosciences), TNF-FITC (Biolegend) and IL-2-PercP eFluor710 (eBioscience) for intracellular staining. PBMCs were washed in PBS and surface-stained at 4 °C for 20 min with saturating concentrations of different combinations of antibodies in the presence of fixable live/dead stain (Invitrogen). Cells were then fixed and permeabilized for detection of intracellular antigens. Cells were acquired on a BD Fortessa X20 using BD FACSDiva8.0 (BD Bioscience) and analysed using FlowJo 10 (Tree Star). t-SNE analysis was performed using the mrc.cytobank platform. Intracellular cytokine staining. PBMCs were thawed and resuspended in RPMI complete medium. After overnight rest at 37 °C and 5%CO 2 , PBMCs were stimulated for 6 h with 2 μg ml −1 HIV-1 Gag pools or CMV pp65 (JPT Peptide Technologies) in the presence of 1 μg ml −1 anti-CD28 and anti-CD49d CoStim antibodies (BD Biosciences), 2 μM Monensin (BD Biosciences), 10 μg ml −1 brefeldin A (Sigma-Aldrich) and anti-CD107a-BV605 (Biolegend). Where indicated and cell numbers permitted, PMBCs were stimulated with 2 μg ml −1 HIV-1 Env, Pol and Nef peptide pools. Following stimulation, virus-specific T cells were identified by intracellular cytokine staining as previously described. In brief, cells were fixed and permeabilized (CytoFix/CytoPerm BD Biosciences) followed by intracellular cytokine staining for IFNγ-PE-Cy7, TNF-FITC and IL-2-PercP eFluor710. Stimulation with 0.005% DMSO in the presence of costimulatory antibodies, protein transport inhibitors and CD107a was performed as a negative control. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper. 
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